Rostislav Petrov

Dr. Rostislav Petrov

Lomonosov Moscow State University
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
RPRostislav Petrov
Rostislav Petrov
SMSofiia R. Mefedova
Sofiia R. Mefedova
EYEmil Yamansarov
Emil Yamansarov
SMSvetlana Yu. Maklakova
Svetlana Yu. Maklakova
DGDmitrii A. Grishin
Dmitrii A. Grishin
AMAlexander G. Majouga
Alexander G. Majouga

21 September 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
IZIgor Zlotnikov
Igor Zlotnikov
AEAlexander Ezhov
Alexander Ezhov
RPRostislav Petrov
Rostislav Petrov
MVMaksim Vigovskiy
Maksim Vigovskiy
OGOlga Grigorieva
Olga Grigorieva
Elena V. KudryashovaElena V. Kudryashova
Elena V. Kudryashova
Bacterial infections and especially resistant strains of pathogens localized in macrophages and granulomas are intractable diseases that pose a threat to millions of people. In this paper, the theoretical and experimental foundations for solving this problem are proposed due to two key aspects. The first is the use of a three-component polymer system for delivering fluoroquinolones to macrophages due to high-affinity interaction with mannose receptors (CD206). Cytometry assay determined that 95.5% macrophage-like cells were FITC-positive after adding high-affine to CD206 trimannoside conjugate HPCD-PEI1.8-triMan, and 61.7% were FITC-positive after adding medium-affine ligand with linear mannose label HPCD-PEI1.8-Man. The second aspect is the use of adjuvants, which are synergists for antibiotics. Using FTIR and NMR spectroscopy, it was shown that molecular containers, namely mannosylated polyethyleneimines (PEIs) and cyclodextrins (CDs), load moxifloxacin (MF) with dissociation constants of the order of 10−4–10−6 M; moreover, due to prolonged release and adsorption on the cell membrane, they enhance the effect of MF. Using CLSM, it was shown that eugenol (EG) increases the penetration of doxorubicin (Dox) into cells by an order of magnitude due to the creation of defects in the bacterial wall and the inhibition of efflux proteins. Fluorescence spectroscopy showed that 0.5% EG penetrates into bacteria and inhibits efflux proteins, which makes it possible to increase the maximum concentration of the antibiotic by 60% and maintain it for several hours until the pathogens are completely neutralized. Regulation of efflux is a possible way to overcome multiple drug resistance of both pathogens and cancer cells.

1 February 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RPRostislav Petrov
Rostislav Petrov
SMSvetlana Yu. Maklakova
Svetlana Yu. Maklakova
YIYan A. Ivanenkov
Yan A. Ivanenkov
SPStanislav Petrov
Stanislav Petrov
OSOlga V. Sergeeva
Olga V. Sergeeva
AMAlexander G. Majouga
Alexander G. Majouga

8 December 2020 in Molecules
Verified
Journal Article
Open access
PDF file
SPStanislav Petrov
Stanislav Petrov
AMAleksei Machulkin
Aleksei Machulkin
AUAnastasia Uspenskaya
Anastasia Uspenskaya
NZNikolai Zyk
Nikolai Zyk
ENEkaterina A. Nimenko
Ekaterina A. Nimenko
Elena BeloglazkinaElena Beloglazkina
Elena Beloglazkina
A strategy for stereoselective synthesis of molecular platform for targeted delivery of bimodal therapeutic or theranostic agents to the prostate-specific membrane antigen (PSMA) receptor was developed. The proposed platform contains a urea-based, PSMA-targeting Glu-Urea-Lys (EuK) fragment as a vector moiety and tripeptide linker with terminal amide and azide groups for subsequent addition of two different therapeutic and diagnostic agents. The optimal method for this molecular platform synthesis includes (a) solid-phase assembly of the polypeptide linker, (b) coupling of this linker with the vector fragment, (c) attachment of 3-aminopropylazide, and (d) amide and carboxylic groups deprotection. A bimodal theranostic conjugate of the proposed platform with a cytostatic drug (docetaxel) and a fluorescent label (Sulfo-Cy5) was synthesized to demonstrate its possible sequential conjugation with different functional molecules.

1 February 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
YIYan A. Ivanenkov
Yan A. Ivanenkov
AMAlexander G. Majouga
Alexander G. Majouga
RPRostislav Petrov
Rostislav Petrov
SPStanislav Petrov
Stanislav Petrov
SKSergey V. Kovalev
Sergey V. Kovalev
EBElena K. Beloglazkina
Elena K. Beloglazkina

4 April 2019 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
MVMark S. Veselov
Mark S. Veselov
YIYan A. Ivanenkov
Yan A. Ivanenkov
RYRenat S. Yamidanov
Renat S. Yamidanov
IOIlya Osterman
Ilya Osterman
PSPetr V. Sergiev
Petr V. Sergiev
ODOlga A. Dontsova
Olga A. Dontsova